Global Nucleic Acid Therapeutics CDMO Market Size is valued at USD 2,540.9 Million in 2024 and is predicted to reach USD 8,688.2 Million by the year 2034 at an 13.2% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Nucleic acids are now recognized as the third most crucial platform for drug discovery, following small molecules and antibodies. Through gene inhibition, addition, replacement, or modification, nucleic acid therapeutics implement synthetic oligonucleotides to achieve curative or enduring effects.The science of nucleic acid therapeutics provides promise for treating disorders that cannot be managed with the drugs that are now available.
Nucleic acid therapeutics deal with nucleic acids (DNA and RNA) or other related chemical compounds. The nucleic acid therapeutics CDMO market is estimated to show high growth over the next few years, driven by the high application potential of nucleic acids for a variety of medical conditions. In addition, the increasing preference for personalized medicine also propels the market growth. Furthermore, continued research and development activities for manufacturing innovative nucleic acid therapeutics are forcing pharmaceutical companies to expand their businesses. Most companies focus on partnerships, acquisitions, collaborations, and mergers with contract development and manufacturing organizations (CDMOs) to seamlessly scale oligonucleotides from research to commercial manufacturing. Therefore, scaling up the products cost-effectively and efficiently from research to commercial quantities is a key challenge to CDMOs.
Other driving factors of the nucleic acid therapeutics CDMO market include the growing demand for nucleic acid therapeutics and the high prevalence of chronic and genetic diseases. Furthermore, advancements in nucleic acid technologies, a rise in R&D investments, increasing FDA approvals of nucleic acid therapeutics, and growing CDMO partnerships and acquisitions are expected to escalate the nucleic acid therapeutics CDMO market growth over the forecast years. However, mass production at low cost, lack of expertise in developing nucleic acid therapeutics, and supply chain challenges are anticipated to hinder the industry growth.
The nucleic acid therapeutics CDMO market is segmented by technology (Column-Based Method and Microarray-Based Method), products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), end-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). North America holds the highest share of this market.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2,540.9 Million |
| Revenue Forecast In 2034 | USD 8,688.2 Million |
| Growth Rate CAGR | CAGR of 13.2% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Therapy / Modality Type, Service Type, Workflow Stage, End-User and Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Agilent Technologies, Inc., Bachem AG, Ajinomoto Bio-Pharma Services, BioSpring GmbH, Exothera SA, Helix Biotech, LGC Group / Axolabs GmbH, Thermo Fisher Scientific Inc. (Patheon), Danaher Corporation (Aldevron), WuXi AppTec Co., Ltd., Merck KGaA (MilliporeSigma Life Science), Curia Global, Inc. (formerly AMRI), KNC Laboratories Co., Ltd., Univercells / Univercells Technologies, Integrated DNA Technologies (IDT, Danaher subsidiary), Evonik Industries AG (Health Care Business Line), Ology Bioservices (now part of National Resilience, Inc.), TriLink BioTechnologies (Maravai LifeSciences), AGC Biologics, Inc., Aurigene Pharmaceutical Services Ltd., PolyPeptide Group AG, Eurofins Scientific SE (Eurofins Genomics Division), Kaneka Eurogentec S.A., Nitto Denko Avecia Inc., ST Pharm Co., Ltd., Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Nucleic Acid Therapeutics CDMO Market By Therapy / Modality Type-
Nucleic Acid Therapeutics CDMO Market By Service Type-
Nucleic Acid Therapeutics CDMO Market By Workflow Stage-
Nucleic Acid Therapeutics CDMO Market By End-User-
Nucleic Acid Therapeutics CDMO Market By Therapeutic Area-
Nucleic Acid Therapeutics CDMO Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nucleic Acid Therapeutics CDMO Market Snapshot
Chapter 4. Global Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Therapy / Modality Type Estimates & Trend Analysis
5.1. by Therapy / Modality Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapy / Modality Type:
5.2.1. mRNA-based Therapeutics
5.2.2. DNA / Plasmid DNA Therapeutics
5.2.3. siRNA (Small Interfering RNA)
5.2.4. Antisense Oligonucleotides (ASOs)
5.2.5. Gene Therapy Products
5.2.6. Others
Chapter 6. Market Segmentation 2: by Service Type Estimates & Trend Analysis
6.1. by Service Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service Type:
6.2.1. Process Development & Optimization
6.2.2. Drug Product (Formulation, Fill & Finish)
6.2.3. Analytical & Quality Control (QC) Services
6.2.4. Regulatory Support & Technology Transfer
6.2.5. Packaging & Fill–Finish Services
Chapter 7. Market Segmentation 3: by Workflow Stage Estimates & Trend Analysis
7.1. by Workflow Stage & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Workflow Stage:
7.2.1. Preclinical Development
7.2.2. Clinical Manufacturing (Phase I–III)
7.2.3. Commercial-Scale Production
Chapter 8. Market Segmentation 4: by End user Estimates & Trend Analysis
8.1. by End user & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End user:
8.2.1. Biopharmaceutical / Biotechnology Companies
8.2.2. Pharmaceutical Companies
8.2.3. Academic & Research Institutes
Chapter 9. Market Segmentation 5: by Therapeutic Area Estimates & Trend Analysis
9.1. by Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:
9.2.1. Oncology
9.2.2. Infectious Diseases
9.2.3. Rare Genetic Disorders
9.2.4. Cardiovascular & Metabolic Disorders
9.2.5. Neurological Disorders
Chapter 10. Nucleic Acid Therapeutics CDMO Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.1.2. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.1.3. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.1.4. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.1.5. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.1.6. North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.2. Europe
10.2.1. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.2.2. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.2.3. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.2.4. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.2.5. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.2.6. Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.3. Asia Pacific
10.3.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.3.2. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.3.3. Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.3.4. Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.3.5. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.3.6. Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.4. Latin America
10.4.1. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.4.2. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.4.3. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.4.4. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.4.5. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.4.6. Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.5. Middle East & Africa
10.5.1. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.5.2. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.5.3. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.5.4. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.5.5. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.5.6. Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Agilent Technologies, Inc.
11.2.2. Bachem AG
11.2.3. Ajinomoto Bio-Pharma Services
11.2.4. BioSpring GmbH
11.2.5. Exothera SA
11.2.6. Helix Biotech
11.2.7. LGC Group / Axolabs GmbH
11.2.8. Thermo Fisher Scientific Inc. (Patheon)
11.2.9. Danaher Corporation (Aldevron)
11.2.10. WuXi AppTec Co., Ltd.
11.2.11. Merck KGaA (MilliporeSigma Life Science)
11.2.12. Curia Global, Inc. (formerly AMRI)
11.2.13. KNC Laboratories Co., Ltd.
11.2.14. Univercells / Univercells Technologies
11.2.15. Integrated DNA Technologies (IDT, Danaher subsidiary)
11.2.16. Evonik Industries AG (Health Care Business Line)
11.2.17. Ology Bioservices (now part of National Resilience, Inc.)
11.2.18. TriLink BioTechnologies (Maravai LifeSciences)
11.2.19. AGC Biologics, Inc.
11.2.20. Aurigene Pharmaceutical Services Ltd.
11.2.21. PolyPeptide Group AG
11.2.22. Eurofins Scientific SE (Eurofins Genomics Division)
11.2.23. Kaneka Eurogentec S.A.
11.2.24. Nitto Denko Avecia Inc.
11.2.25. ST Pharm Co., Ltd.
11.2.26. Other Prominent Players